Evidence map›Paper›PMID 31734930›Full record

ReviewCurrent cardiology reports2019

Treatment of Functional Mitral Regurgitation in Heart Failure.

Enrico Fabris, Antonio De Luca, Giancarlo Vitrella, Davide Stolfo, Marco Masè, Renata Korcova, Marco Merlo, Serena Rakar, Arnoud W J Van't Hof, Elvin Kedhi and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Enrico FabrisCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy. enrico.fabris@hotmail.it.
Antonio De LucaCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Giancarlo VitrellaCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Davide StolfoCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Marco MasèCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Renata KorcovaCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Marco MerloCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Serena RakarCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Arnoud W J Van't HofDepartment of Cardiology, Maastricht University Medical Center, Maastricht, the Netherlands.
Elvin KedhiAZ Sint-Jan Brugge, Bruges, Belgium.
Andrea PerkanCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
Gianfranco SinagraCardiovascular Department, University of Trieste, Via Valdoni 7, 34129, Trieste, Italy.
University of Trieste · ITAZ Sint-Jan · BEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewTo analyze the current state of the art of functional mitral regurgitation (FMR) treatment. RECENT

findingsThe first-line treatment of severe FMR consists of guideline medical therapy (GMT) and resynchronization therapy when indicated; the impact of new medical therapies like sacubitril/valsartan needs further assessment. Valvular intervention may be considered in FMR symptomatic patients despite GMT, and can be performed surgically or percutaneously. MitraClip is a safe percutaneous procedure associated with symptoms improvement. Recently, the COAPT trial showed superior outcomes for MitraClip versus GMT contrasting the MITRA-FR trial which showed no benefit of MitraClip compared with GMT. These results should be interpreted as complementary rather than opposite. The COAPT trial provided a "proof of concept" that percutaneous treatment of severe FMR in patients without too advanced left ventricular disease translates into a prognostic benefit. Careful patient selection will play a critical role in defining the clinical niche for successful interventions.

Indexed as

Heart FailureHeart Valve Prosthesis ImplantationMitral Valve InsufficiencyFemaleHumansMaleMitral ValveTreatment OutcomeFunctional mitral regurgitationHeart failureHeart teamMitraClipMitral valve repairTranscatheter interventions

Identifiers

PMID31734930
OpenAlexW2985289856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.